文献速递乳腺PET

动态18F-FDG PET/CT机器学习预测转移性乳腺癌预后

Machine Learning-driven Prognostic Stratification in Metastatic Breast Cancer Using Dynamic 18F-FDG PET/CT: A Multidimensional Study Integrating Pathomics and Plasma Proteomics.
PubMed 文献 · Acad Radiol · 2026-08-15

本研究回顾性纳入112例转移性乳腺癌患者,提取基线与治疗后的18F-FDG PET/CT代谢及动态生物标志物,构建随机生存森林预后模型(dPMBC)。该模型训练集AUC为0.881,测试集AUC为0.807,可在一线治疗期间早期识别高危患者。病理组学与血浆蛋白质组学进一步提示高危组存在细胞外基质重塑、核异型性及GART相关代谢重编程。

要点

  • 治疗后SUVmax2与ΔSULmax是独立预后因素,可纳入疗效评估报告。
  • SUVmax2在模型中最具预测贡献,报告时应明确记录治疗后病灶代谢值。
  • dPMBC模型有助于一线治疗期间早期识别高危患者,指导个体化调整。

核心结论

  • 动态PET/CT预后模型(dPMBC)整合基线与治疗后PET生物标志物,具有良好的预测性能与生物学可解释性。
  • 病理组学提示高危患者存在细胞外基质重塑与核异型性的独特形态学演化特征。
  • 血浆蛋白质组学提示高危组以GART为核心的代谢重编程及HLA-C、STAT1相关免疫改变。

研究设计与样本

  • 单中心回顾性研究,纳入112例转移性乳腺癌患者,提取系列基线与治疗后18F-FDG PET/CT图像参数。
  • 采用Cox回归筛选独立预后生物标志物,通过多种机器学习算法构建预后模型,用SHAP解释模型。
  • 病理组学分析纳入45例样本,血浆蛋白质组学分析纳入48例样本。

关键影像表现/征象

  • 高危患者病理组学显示细胞外基质重塑和核异型性等形态学演化特征。
  • SHAP分析显示SUVmax2是模型中最具影响力的预测特征。

诊断标准与关键数值

  • 治疗后的SUVmax2与动态ΔSULmax被确定为无进展生存期的独立预后因素。
  • dPMBC模型训练集AUC为0.881,测试集AUC为0.807。

临床应用与阅片要点

  • 报告系统中应规范记录基线和治疗后SUVmax及SULmax动态变化值,这些参数被证实为独立预后因素。
  • 基于动态PET参数的dPMBC模型可用于一线治疗期间对转移性乳腺癌患者进行风险分层,对高危患者加强监测。

局限性

  • 回顾性单中心研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Existing baseline-dependent metastatic breast cancer (MBC) prognostic systems remain limited in capturing tumor evolution under therapeutic pressure. We aimed to develop a dynamic 18F-FDG PET/CT-derived machine learning prognostic model and systematically explore its biological rationale using pathomics and proteomics.

MATERIALS AND METHODS: PET metabolic and dynamic biomarkers were extracted from serial baseline and post-treatment 18F-FDG PET/CT images of 112 retrospectively included MBC patients. Independent prognostic biomarkers were identified using Cox regression. Prognostic models were constructed through multiple machine learning algorithms, with interpretability provided by SHapley Additive exPlanations (SHAP). Pathomics (n = 45) and plasma proteomics (n = 48) analyses were performed to characterize risk-associated biological features.

RESULTS: Post-treatment metabolic (SUVmax2) and dynamic (ΔSULmax) PET biomarkers emerged as independent prognostic factors for progression-free survival. The final random survival forest model, termed the dynamic PET/CT-based MBC (dPMBC) prognostic model, achieved favorable prognostic stratification, yielding area under the curve values of 0.881 and 0.807 in the training and testing cohorts, respectively. SHAP identified SUVmax2 as the most influential predictive feature. Pathomics revealed distinct morphological evolution in high-risk patients, characterized by extracellular matrix remodeling and nuclear atypia. Plasma proteomics highlighted GART-centric metabolic reprogramming and immune-related alterations involving HLA-C and STAT1 within this high-risk group.

CONCLUSION: The dPMBC prognostic model, integrating dynamic PET biomarkers, demonstrates promising predictive performance and biological interpretability. It enables early identification of high-risk patients during first-line therapy, supporting closer monitoring and timely individualized treatment adjustment. Pathomics and proteomics further provide biological insights into PET/CT-derived risk stratification in MBC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Guo, Yu, Wang, et al. Machine Learning-driven Prognostic Stratification in Metastatic Breast Cancer Using Dynamic 18F-FDG PET/CT: A Multidimensional Study Integrating Pathomics and Plasma Proteomics. Acad Radiol. 2026. PMID: 42904330. doi:10.1016/j.acra.2026.07.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。